1. Market Research
  2. > All Companies
  3. > Cervical Cancer - Pipeline Review, H1 2015

Cervical Cancer - Pipeline Review, H1 2015

  • June 2015
  • -
  • Global Markets Direct
  • -
  • 308 pages

Cervical Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cervical Cancer - Pipeline Review, H1 2015’, provides an overview of the Cervical Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cervical Cancer - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cervical Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Cervical Cancer - Overview 11
Pipeline Products for Cervical Cancer - Comparative Analysis 12
Cervical Cancer - Therapeutics under Development by Companies 13
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 18
Cervical Cancer - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Cervical Cancer - Products under Development by Companies 24
Cervical Cancer - Products under Investigation by Universities/Institutes 29
Cervical Cancer - Companies Involved in Therapeutics Development 31
3SBio Inc. 31
Admedus Ltd 32
Advaxis, Inc. 33
Amorfix Life Sciences Ltd. 34
Antigen Express, Inc. 35
Arbor Vita Corporation 36
AstraZeneca Plc 37
AVEO Pharmaceuticals, Inc. 38
Azaya Therapeutics Incorporated 39
Cancer Research Technology Limited 40
Chong Kun Dang Pharmaceutical Corp. 41
Critical Outcome Technologies Inc. 42
CZ BioMed Corp 43
Daiichi Sankyo Company, Limited 44
EyeGene, Inc. 45
F. Hoffmann-La Roche Ltd. 46
Formune S.L. 47
Genexine, Inc. 48
Genmab A/S 49
Genticel S.A. 50
GlaxoSmithKline Plc 51
Indian Immunologicals Limited 52
Inovio Pharmaceuticals, Inc. 53
ISA Pharmaceuticals B.V. 54
Karyopharm Therapeutics, Inc. 55
Kite Pharma, Inc. 56
LondonPharma Ltd 57
MedImmune, LLC 58
MEI Pharma, Inc. 59
Nanotherapeutics, Inc. 60
Nektar Therapeutics 61
Novartis AG 62
Oncobiologics, Inc. 63
Otsuka Holdings Co., Ltd. 64
Redbiotec AG 65
Rexahn Pharmaceuticals, Inc. 66
Sanofi 67
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 68
Shantha Biotechnics Limited 69
Sirnaomics, Inc. 70
Taiho Pharmaceutical Co., Ltd. 71
Theravectys S.A. 72
Vaccibody AS 73
VLPbio 74
Zeria Pharmaceutical Co Ltd 75
Zydus Cadila Healthcare Limited 76
Cervical Cancer - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Target 79
Assessment by Mechanism of Action 83
Assessment by Route of Administration 86
Assessment by Molecule Type 88
Drug Profiles 90
(tegafur + gimeracil + oteracil) - Drug Profile 90
ADXS-HPV - Drug Profile 93
AEH-10p - Drug Profile 97
AMF-3d19 - Drug Profile 98
aminolevulinic acid hydrochloride - Drug Profile 99
Antisense Oligonucleotides for Cervical Cancer - Drug Profile 100
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 101
artemether - Drug Profile 102
AV-203 - Drug Profile 104
AVC-7 - Drug Profile 105
AZD-1775 - Drug Profile 106
AZD-5363 - Drug Profile 108
bevacizumab - Drug Profile 110
bevacizumab biosimilar - Drug Profile 115
bevacizumab biosimilar - Drug Profile 116
BLI-1004 - Drug Profile 117
BPR-1K653 - Drug Profile 118
buparlisib hydrochloride - Drug Profile 119
Cell Therapy for Cervical Carcinoma - Drug Profile 123
Cell Therapy for HPV Associated Cancers - Drug Profile 124
Cell Therapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 125
Cell Therapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 127
CerviVax - Drug Profile 129
Cervlysis - Drug Profile 130
CIGB-228 - Drug Profile 131
CIGB-300 - Drug Profile 132
CKD-12201 - Drug Profile 134
COTI-2 - Drug Profile 135
crocetin - Drug Profile 138
docetaxel liposomal - Drug Profile 140
durvalumab + tremelimumab - Drug Profile 142
EDA-HPVE7 - Drug Profile 144
EG-HPV - Drug Profile 145
etirinotecan pegol - Drug Profile 146
everolimus - Drug Profile 149
GSK-2849330 - Drug Profile 155
GX-188E - Drug Profile 156
human papillomavirus vaccine - Drug Profile 157
human papillomavirus vaccine - Drug Profile 158
human papillomavirus vaccine - Drug Profile 159
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 161
HuMax-TF-ADC - Drug Profile 162
INO-3112 - Drug Profile 163
ISA-101 - Drug Profile 164
Lovaxin S - Drug Profile 165
mapatumumab - Drug Profile 166
ME-344 - Drug Profile 168
nimotuzumab - Drug Profile 170
NTCP-02 - Drug Profile 173
OPB-111001 - Drug Profile 174
OTAC-DCtag - Drug Profile 175
patritumab - Drug Profile 176
pazopanib hydrochloride - Drug Profile 178
Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Oncology - Drug Profile 184
Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 185
ProCervix - Drug Profile 186
RA-190 - Drug Profile 188
RBT-201 - Drug Profile 189
RX-3117 - Drug Profile 190
S-009131 - Drug Profile 192
SAR-408701 - Drug Profile 193
selinexor - Drug Profile 194
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 199
Small Molecules for Cervival Cancer - Drug Profile 200
SSS-08 - Drug Profile 201
STP-909 - Drug Profile 202
TA-CIN - Drug Profile 203
Tenacinol - Drug Profile 205
TF-011 Monomethyl Auristatin E - Drug Profile 206
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 208
Triapine - Drug Profile 210
Vaccine for Cervical and Head and Neck Cancers - Drug Profile 212
Vaccine for Cervical Cancer - Drug Profile 213
Vaccine for Cervical Cancer - Drug Profile 214
vaccine for cervical cancer - Drug Profile 215
Vaccine for Cervical Cancer and Genital Warts - Drug Profile 216
Vaccine for Cervical Cancer, Head And Neck Cancer - Drug Profile 217
Vaccine for HPV Associated Cancers - Drug Profile 218
Vaccine for Ovarian Cancer and Cervical Cancer - Drug Profile 219
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 220
Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile 221
VB-1016 - Drug Profile 222
Vvax-001 - Drug Profile 223
Z-100 - Drug Profile 224
Cervical Cancer - Recent Pipeline Updates 225
Cervical Cancer - Dormant Projects 287
Cervical Cancer - Discontinued Products 291
Cervical Cancer - Product Development Milestones 292
Featured News and Press Releases 292
Appendix 301
Methodology 301
Coverage 301
Secondary Research 301
Primary Research 301
Expert Panel Validation 301
Contact Us 301
Disclaimer 302

List of Tables
Number of Products under Development for Cervical Cancer, H1 2015 17
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Comparative Analysis by Unknown Stage Development, H1 2015 29
Products under Development by Companies, H1 2015 30
Products under Development by Companies, H1 2015 (Contd..1) 31
Products under Development by Companies, H1 2015 (Contd..2) 32
Products under Development by Companies, H1 2015 (Contd..3) 33
Products under Development by Companies, H1 2015 (Contd..4) 34
Products under Investigation by Universities/Institutes, H1 2015 35
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 36
Cervical Cancer - Pipeline by 3SBio Inc., H1 2015 37
Cervical Cancer - Pipeline by Admedus Ltd, H1 2015 38
Cervical Cancer - Pipeline by Advaxis, Inc., H1 2015 39
Cervical Cancer - Pipeline by Amorfix Life Sciences Ltd., H1 2015 40
Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2015 41
Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2015 42
Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2015 43
Cervical Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 44
Cervical Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2015 45
Cervical Cancer - Pipeline by Cancer Research Technology Limited, H1 2015 46
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 47
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015 48
Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2015 49
Cervical Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 50
Cervical Cancer - Pipeline by EyeGene, Inc., H1 2015 51
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 52
Cervical Cancer - Pipeline by Formune S.L., H1 2015 53
Cervical Cancer - Pipeline by Genexine, Inc., H1 2015 54
Cervical Cancer - Pipeline by Genmab A/S, H1 2015 55
Cervical Cancer - Pipeline by Genticel S.A., H1 2015 56
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015 57
Cervical Cancer - Pipeline by Indian Immunologicals Limited, H1 2015 58
Cervical Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 59
Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2015 60
Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 61
Cervical Cancer - Pipeline by Kite Pharma, Inc., H1 2015 62
Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2015 63
Cervical Cancer - Pipeline by MedImmune, LLC, H1 2015 64
Cervical Cancer - Pipeline by MEI Pharma, Inc., H1 2015 65
Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2015 66
Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2015 67
Cervical Cancer - Pipeline by Novartis AG, H1 2015 68
Cervical Cancer - Pipeline by Oncobiologics, Inc., H1 2015 69
Cervical Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 70
Cervical Cancer - Pipeline by Redbiotec AG, H1 2015 71
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 72
Cervical Cancer - Pipeline by Sanofi, H1 2015 73
Cervical Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 74
Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H1 2015 75
Cervical Cancer - Pipeline by Sirnaomics, Inc., H1 2015 76
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 77
Cervical Cancer - Pipeline by Theravectys S.A., H1 2015 78
Cervical Cancer - Pipeline by Vaccibody AS, H1 2015 79
Cervical Cancer - Pipeline by VLPbio, H1 2015 80
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2015 81
Cervical Cancer - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 82
Assessment by Monotherapy Products, H1 2015 83
Assessment by Combination Products, H1 2015 84
Number of Products by Stage and Target, H1 2015 86
Number of Products by Stage and Mechanism of Action, H1 2015 90
Number of Products by Stage and Route of Administration, H1 2015 93
Number of Products by Stage and Molecule Type, H1 2015 95
Cervical Cancer Therapeutics - Recent Pipeline Updates, H1 2015 231
Cervical Cancer - Dormant Projects, H1 2015 293
Cervical Cancer - Dormant Projects (Contd..1), H1 2015 294
Cervical Cancer - Dormant Projects (Contd..2), H1 2015 295
Cervical Cancer - Dormant Projects (Contd..3), H1 2015 296
Cervical Cancer - Discontinued Products, H1 2015 297

List of Figures
Number of Products under Development for Cervical Cancer, H1 2015 17
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 19
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Products, H1 2015 28
Assessment by Monotherapy Products, H1 2015 83
Assessment by Combination Products, H1 2015 84
Number of Products by Top 10 Targets, H1 2015 85
Number of Products by Stage and Top 10 Targets, H1 2015 85
Number of Products by Top 10 Mechanism of Actions, H1 2015 89
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 89
Number of Products by Top 10 Routes of Administration, H1 2015 92
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 92
Number of Products by Top 10 Molecule Types, H1 2015 94
Number of Products by Stage and Top 10 Molecule Types, H1 2015 94

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

  • $ 3 995
  • Company report
  • July 2015
  • by Global Data

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023 Summary Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma ...

Liver Cancer - Pipeline Review, H1 2015

Liver Cancer - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Liver Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Liver Cancer - Pipeline Review, H1 2015’, provides an overview of the Liver Cancer’s therapeutic pipeline. This report ...

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015’, provides an overview of the Multiple ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.